
Sign up to save your podcasts
Or


In part one of this three-part series, Dr. Justin Abbatemarco and Dr. Jiwon Oh discuss how Bruton Tyrosine Kinase (BTK) Inhibitors work and how they vary from other disease-modifying therapies.
Show reference:
https://www.nejm.org/doi/full/10.1056/NEJMoa2415985
https://www.nejm.org/doi/full/10.1056/NEJMoa2415988
By American Academy of Neurology4.8
132132 ratings
In part one of this three-part series, Dr. Justin Abbatemarco and Dr. Jiwon Oh discuss how Bruton Tyrosine Kinase (BTK) Inhibitors work and how they vary from other disease-modifying therapies.
Show reference:
https://www.nejm.org/doi/full/10.1056/NEJMoa2415985
https://www.nejm.org/doi/full/10.1056/NEJMoa2415988

320 Listeners

497 Listeners

293 Listeners

50 Listeners

295 Listeners

3,341 Listeners

12 Listeners

1,149 Listeners

23 Listeners

194 Listeners

92 Listeners

513 Listeners

369 Listeners

189 Listeners

82 Listeners